Abstract 36P
Background
ICIs targeting programmed death cell 1 (PD-1) and its ligand 1 (PD-L1) revolutionized the management of many types of tumors. However, almost half of treated patients do not achieve any clinical benefit while another portion of patients (10-15%) develop severe irAEs. Consequently, biomarkers are needed to identify which patients have a higher likelihood of achieving a clinical benefit and/or developing severe irAEs.
Methods
We assessed the role of sB7-H3 as a biomarker for predicting the clinical benefit and the occurrence of irAEs in advanced cancer patients treated with ICIs. sB7-H3 levels were evaluated by ELISA assay before starting (T0) and after three months of anti PD-1/PD-L1 therapy (T1). Clinical-pathological characteristics and sB7-H3 levels were correlated with survival outcomes (PFS and OS) using log-rank test. Grade 1-2 and 3-4 irAE rates were correlated with the levels of sB7-H3 using one-way ANOVA.
Results
Sixty-four patients including non-small cell lung cancer (36), renal cell carcinoma (16), head and neck squamous cell carcinoma (6) and melanoma (6) were treated with anti-PD-1/PD-L1 therapy as second-line therapy. At a median follow-up of 25.37 months, median PFS and OS were 7.13 and 10.80 months, respectively. Grade 1-2 and grade 3-4 irAEs were reported in 52 (81.25%) and 10 (15.63%) of treated patients, respectively. The levels of sB7-H3 both at T0 and T1 were significantly correlated with PFS (p=0.048 and 0.05) and OS (p=0.018 and 0.042). Specifically, patients displaying lower levels of sB7-H3 have an increased PFS and OS as compared to those with higher levels. In addition, lower levels of sB7-H3 both at T0 and T1 were correlated with the occurrence of grade 3-4 irAEs (p= 0.005 and p=0.001). No further significant correlation between clinical-pathological characteristics and survival outcomes or sB7-H3 levels was found.
Conclusions
Our findings have clinical relevance since i) identify sB7-H3 as an efficient biomarker for predicting clinical benefit and occurrence of irAEs in advanced cancer patients treated with ICIs; and ii) propose B7-H3 as a mechanism of resistance to ICIs.
Legal entity responsible for the study
Prof Francesco Sabbatino.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
Resources:
Abstract
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
Resources:
Abstract
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
Resources:
Abstract
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
Resources:
Abstract
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
Resources:
Abstract
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
Resources:
Abstract
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
Resources:
Abstract
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract